Unlock this StockReport nowClick to Unlock

ReNeuron Share Price

RENE 220p -17.5  -7.4%
19/06/19 3.00k
StockRank

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Mar 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p +12.8%

FINANCIAL BRIEF: For the six months ended 30 September 2018, ReNeuron Group Plc revenues increased 13% to £27K. Net loss decreased 44% to £5.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income grants & Exclusivity fee increase from £240K to £2.4M (income), Research and development costs decrease of 12% to £7.5M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
E-
E-
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Sep '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Mar 2019
31st Mar 2020

Price Target: 5.81
(+164.31% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
4 brokers Broker Consensus Trend
Broker Recommendations for ReNeuron
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 1

Named Brokers and Analysts
Stifel Nicolaus and Company, Incorporated Christian Glennie , Maxim Group Jason McCarthy , Edison Investment Research Andy Smith , N+1 Singer Jens Lindqvist ,

Profile Summary

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.

Directors: Olav Hellebo (CEO) , Michael Hunt (CFO) , John Sinden (CSO) 62, Sharon Grimster (VPR) , Richard Beckman (OTH) , Randolph Corteling (OTH) , Shaun Stapleton (OTH) , John Berriman (NEC) 68, Simon Cartmell (NED) 47, Timothy Corn (NED) 65, Claudia D'Augusta (NED) , Mark Docherty (NED) ,

No. of Employees: 62 No. of Shareholders: n/a


Last Annual March 31st, 2018
Last Interim September 30th, 2018
Incorporated June 7, 2005
Public Since August 12, 2005
Shares in Issue 31,801,617
Free Float 30.5m (95.9%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

RENE Share Price Performance RENE Share Price Quote
220p
-17.5  -7.4%
Traded 4:18pm · Minimum 15 min delayed · NMS: 3.00k

Latest RENE News Announcements (delayed)

Upcoming RENE Events
Thursday 27th June, 2019 (estimate)
Full Year 2019 ReNeuron Group PLC Earnings Release
Thursday 11th July, 2019
Full Year 2019 ReNeuron Group PLC Earnings Call

Recent ↓
Friday 14th December, 2018
Half Year 2019 ReNeuron Group PLC Earnings Call
Friday 14th December, 2018
Half Year 2019 ReNeuron Group PLC Earnings Release
Thursday 6th September, 2018
ReNeuron Group PLC at Rodman & Renshaw Global Investment Conference
Friday 29th June, 2018 (estimate)
Full Year 2018 ReNeuron Group PLC Earnings Release
Wednesday 24th January, 2018
ReNeuron Group PLC Reverse Split For RENE
Thursday 14th December, 2017
Half Year 2018 ReNeuron Group PLC Earnings Call
Thursday 14th December, 2017
Half Year 2018 ReNeuron Group PLC Earnings Release
Tuesday 14th November, 2017
ReNeuron Group PLC at Stifel Healthcare Conference
Monday 11th September, 2017
ReNeuron Group PLC at Rodman & Renshaw Global Investment Conference
Thursday 29th June, 2017
Full Year 2017 ReNeuron Group PLC Earnings Call
Thursday 29th June, 2017
Full Year 2017 ReNeuron Group PLC Earnings Release
Monday 5th December, 2016
Half Year 2016 ReNeuron Group PLC Earnings Call
Monday 5th December, 2016
Half Year 2016 ReNeuron Group PLC Earnings Release
Tuesday 15th November, 2016
ReNeuron Group PLC at Stifel Healthcare Conference
Thursday 7th July, 2016
Full Year 2016 ReNeuron Group PLC Earnings Call
Thursday 7th July, 2016
Full Year 2016 ReNeuron Group PLC Earnings Release
Wednesday 2nd September, 2015 (estimate)
ReNeuron Group PLC Annual Shareholders Meeting
Tuesday 13th January, 2015
ReNeuron Group PLC at EBD Biotech Showcase
Tuesday 2nd September, 2014
ReNeuron Group PLC Annual Shareholders Meeting


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy RENE

Access RENE Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis